10,13,13-Trimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-triene-1,4-diol

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 6,7-苯并吗啡烷
• 英文名称: 10,13,13-Trimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-triene-1,4-diol
• 英文别名: 10,13,13-trimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-triene-1,4-diol
• 化学式: C₁₅H₂₁NO₂
• 分子量: 247.33
• InChiKey: BYWJZXFAANYJND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  43.7
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Benzomorphan Analogs and the Use Thereof
  申请人：LOCKMAN Jeffrey

  公开号：US20140135351A1

  公开（公告）日：2014-05-15

  The present invention is directed to Benzomorphan Analog compounds of the Formula I″, Formula IA″, Formula IB″, Formula IC″, or Formula ID″ as shown below; and related Formula I′, Formula IA′, Formula IB′, Formula IC′, or Formula ID′; Formula I, Formula IA, Formula IB, Formula IC, or Formula ID; wherein R 1 , R 2a , R 2b , R 3 and R 4 are as defined herein. Compounds of the Invention are useful for treating pain, constipation, and other conditions modulated by activity of opioid and ORL-1 receptors.

  本发明涉及以下所示的Formula I″、Formula IA″、Formula IB″、Formula IC″或Formula ID″的苯吗啡类似物化合物；以及相关的Formula I′、Formula IA′、Formula IB′、Formula IC′或Formula ID′；Formula I、Formula IA、Formula IB、Formula IC或Formula ID；其中R1、R2a、R2b、R3和R4如本文所定义。本发明的化合物可用于治疗疼痛、便秘以及受阿片类和ORL-1受体活性调节的其他疾病。
• BENZOMORPHAN ANALOGS AND THE USE THEREOF
  申请人：Purdue Pharma L.P.

  公开号：US20140221419A1

  公开（公告）日：2014-08-07

  The present invention is directed to Benzomorphan Analog compounds of the Formula I-ID as shown below, wherein R 1 , R 2a , R 2b , R 3 and R 4 are as defined herein. Compounds of the Invention are useful for treating pain, constipation, and other conditions modulated by activity of opioid and ORL-1 receptors.

  本发明涉及如下所示的Formula I-ID的苯吗啉类似化合物，其中R1、R2a、R2b、R3和R4的定义如本文所述。本发明的化合物可用于治疗疼痛、便秘以及其他受阿片类和ORL-1受体活性调节的疾病。
• BENZOMORPHAN COMPOUNDS AS OPIOID RECEPTORS MODULATORS
  申请人：Purdue Pharma L.P.

  公开号：US20150210646A1

  公开（公告）日：2015-07-30

  The present invention is directed to Benzomorphan Analog compounds of the Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (ID) as shown below, wherein R 1 , R 2a , R 2b , R 3 , R 4 , Z, and G are as defined herein. Compounds of the Invention are useful for treating pain, constipation, and other conditions modulated by activity of opioid and ORL-1 receptors.

  本发明涉及以下式子所示的苯并吗啡类似物化合物的公式（I），公式（IA），公式（IB），公式（IC）或公式（ID），其中R1，R2a，R2b，R3，R4，Z和G如本文所定义。 本发明的化合物适用于治疗由阿片样和ORL-1受体活性调节的疼痛，便秘和其他症状。
• Benzomorphan analogs and the use thereof
  申请人：Purdue Pharma L.P.

  公开号：US10130615B2

  公开（公告）日：2018-11-20

  In one aspect, the invention provides compounds of Formula (I) or (II): (I) or (II) and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3, R4, Z and G are defined as set forth in the disclosure. The invention also provides compounds of Formulae A and B and pharmaceutically acceptable salts and solvates thereof. Other aspects of the invention include the use of compounds of Formulae I, II, A, and B, and pharmaceutically acceptable salts and solvates thereof for the treatment of disorders responsive to modulation of one or more opioid receptors. In certain embodiments, the Compounds of the Invention are useful for treating pain.

  在一个方面，本发明提供了式(I)或(II)化合物： (I)或(II)及其药学上可接受的盐和溶解物，其中 R1、R2a、R2b、R3、R4、Z 和 G 的定义如公开内容所述。本发明还提供了式 A 和 B 的化合物及其药学上可接受的盐和溶剂。本发明的其它方面包括式I、II、A和B化合物及其药学上可接受的盐和溶液用于治疗对一种或多种阿片受体的调节有反应的疾病。在某些实施方案中，本发明化合物可用于治疗疼痛。
• BENZOMORPHAN ANALOGS And Use Thereof
  申请人：Purdue Pharma L.P.

  公开号：US20170073313A1

  公开（公告）日：2017-03-16

  The invention provides compounds as represented by Formula I or I′ and pharmaceutically acceptable salts, solvates, and diastereomers thereof: Wherein R 1 , R 2 , R 2a , R 3 , and R 4 are defined in the disclosure. The invention also provides compounds of Formulae II, III, and A-H, and pharmaceutically acceptable salts, solvates, and diastereomers thereof. In certain embodiments, Compounds of the Invention are useful for treating pain, constipation, and other conditions as delineated in the disclosure. Without wishing to be bound by any theory, it is believed that Compounds of the Invention are effective in treating conditions that are modulated by activity of opioid and/or ORL-1 receptors.